Mark Alan Goldberg, EVP, Medical & Reg. Strategy at SYNAGEVA BIOPHARMA CORP (GEVA), sold 13,579 shares at $65.06 ($883K) on 2014-09-17, disclosed to the SEC on 2014-09-18.
Scheduled sale ($883k) by EVP, Medical & Reg. Strategy under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $65.01 | 9,379 | $610K | 69.1% |
| 2 | $65.06 | 4,200 | $273K | 30.9% |
| Total | $65.03 avg | 13,579 | $883K | 100% |
| Filing → |
| BPMC | SELL | 2020-12-22 | $654K | — | Filing → |
| BPMC | SELL | 2020-12-15 | $627K | — | Filing → |
| BPMC | SELL | 2020-12-03 | $600K | — | Filing → |